Last reviewed · How we verify
Domeboro (ALUMINUM ACETATE)
At a glance
| Generic name | ALUMINUM ACETATE |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
- Skin irritation
Common side effects
Key clinical trials
- TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus (PHASE2)
- A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is (PHASE3)
- Effect of Laser Acupuncture for Treating Monosymptomatic Nocturnal Enuresis in Adolescent Females (NA)
- Application of Vitamin E on Anal Fissure (PHASE3)
- Occlusion vs Standard Treatment for the Treatment of Herpes Zoster (NA)
- Evaluation of Allium Ampeloprasum Spp.Iranicum Cream Effect for the Management of Hemorrhoids Symptoms (PHASE1,PHASE2)
- Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating (NA)
- Optical Coherence Tomography Quantitative Analysis of Changes in Anterior Chamber After Laser Peripheral Lridotomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Domeboro CI brief — competitive landscape report
- Domeboro updates RSS · CI watch RSS
- Bayer portfolio CI